Short-Term Intraocular Pressure Trends Following Intravitreal Pegaptanib (Macugen) Injection

ArticleinAmerican Journal of Ophthalmology 141(1):200-1 · February 2006with7 Reads
Impact Factor: 3.87 · DOI: 10.1016/j.ajo.2005.07.053 · Source: PubMed


    To report the changes and trends in intraocular pressures (IOP) following intravitreal injection of Pegaptanib (Macugen) for the treatment of exudative age-related macular degeneration.
    Retrospective chart review.
    Review of 79 patients who underwent 122 consecutive Pegaptanib injections. Analysis of the short-term effect of Pegaptanib injections on IOP was performed.
    Baseline mean IOP was 15.73 +/- 3.41 mm Hg (mean +/- standard deviation) with a range of 9 to 27 mm Hg. Postinjection mean IOP was 24.47 +/- 6.29 mm Hg with a range of 8 to 36 mm Hg. Mean IOP change from baseline to roughly 30 minutes after Pegaptanib injection was 8.74 +/- 7.23 mm Hg. At the 5- to 7-day follow-up visit, IOP had normalized.
    Pegaptanib injection in this limited series seems to be safe from an IOP standpoint in the short-term. IOP monitoring postinjection may not be necessary.